CLL Advocates Network (@clladvocates) 's Twitter Profile
CLL Advocates Network

@clladvocates

Improve CLL patient outcomes as a global network of CLL patient advocates.
Contact: [email protected]

ID: 721198871939035136

linkhttps://www.clladvocates.net calendar_today16-04-2016 04:49:45

3,3K Tweet

1,1K Followers

1,1K Following

CLL Advocates Network (@clladvocates) 's Twitter Profile Photo
CLL Advocates Network
@clladvocates

2 months ago

Presented at #EHA2025: Among patients with CLL undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial nej.md/3SMNdC4

Presented at #EHA2025: Among patients with CLL undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial nej.md/3SMNdC4